Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus.
about
Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK.Cost-effectiveness analysis of liraglutide versus sitagliptin or exenatide in patients with inadequately controlled Type 2 diabetes on oral antidiabetic drugs in Greece.Cost-utility analysis of glucagon-like Peptide-1 agonists compared with dipeptidyl peptidase-4 inhibitors or neutral protamine hagedorn Basal insulin as add-on to metformin in type 2 diabetes in swedenEvaluating the Long-Term Cost-Effectiveness of Daily Administered GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes in the United Kingdom.How Consistent is the Relationship between Improved Glucose Control and Modelled Health Outcomes for People with Type 2 Diabetes Mellitus? a Systematic Review.Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in SpainThyroid safety in patients treated with liraglutide.Review of models used in economic analyses of new oral treatments for type 2 diabetes mellitus.Evidence-based practice use of incretin-based therapy in the natural history of diabetes.Cost effectiveness of liraglutide in type II diabetes: a systematic review.Evaluation of the long-term cost-effectiveness of liraglutide vs lixisenatide for treatment of type 2 diabetes mellitus in the UK setting.The place of DPP-4 inhibitors in the treatment algorithm of diabetes type 2: a systematic review of cost-effectiveness studies.INCORPORATING ENVIRONMENTAL OUTCOMES INTO A HEALTH ECONOMIC MODEL.Incretin therapy for type 2 diabetes in Spain: a cost-effectiveness analysis of liraglutide versus sitagliptin.Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China.Cost-Effectiveness Analysis of Incretin Therapy for Type 2 Diabetes in Spain: 1.8 mg Liraglutide Versus Sitagliptin.Comparison of diabetes-associated secondary healthcare utilization between alternative oral antihyperglycaemic dual therapy combinations with metformin in patients with type 2 diabetes: an observational cohort study.
P2860
Q33732593-6B92516C-EC5A-4309-9911-BC70E9F42819Q34266016-3FE456F5-90DC-4A0A-81A9-FC6766B14FFBQ34726534-061734C6-6D65-42CE-A113-2CFF527DBB54Q37639302-7601F7CA-8D0D-4A17-9A2B-B044490EC110Q37639785-0ED491C0-A9BB-4E73-9149-27BAB9EED866Q37737468-12EBB7DF-1299-41BF-9160-74FB13399229Q38088551-84AD51E7-EDB4-4CD8-B9AE-A165F41B7380Q38172859-E8DF4535-D2C6-47EB-ADB1-7B1D93ADAB98Q38219482-5E990B91-2FFD-405D-B340-2B690993FAE5Q38232870-9821249E-1CBA-4B80-8ED8-7B07916CDCC0Q38765656-EA56AA1C-960A-456B-B838-DDD49D4C38B2Q38983533-AC0A7D50-6EF4-4A70-92AC-14E3DCFE3B30Q39033690-E0FCF317-1FD6-482B-A539-52DC8D95DA49Q39331320-93AD3AE3-8293-4324-AC01-7C0D268D1347Q39548089-6E481A80-1C4E-46BD-BF42-EEEA6AB9BB6BQ41288731-B459565D-6545-448C-9E4E-99AC19F0EF55Q41310853-ECA50CAC-A955-48DA-9CA1-714157F56837
P2860
Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Cost-utility analysis of lirag ...... y in Type 2 diabetes mellitus.
@ast
Cost-utility analysis of lirag ...... y in Type 2 diabetes mellitus.
@en
type
label
Cost-utility analysis of lirag ...... y in Type 2 diabetes mellitus.
@ast
Cost-utility analysis of lirag ...... y in Type 2 diabetes mellitus.
@en
prefLabel
Cost-utility analysis of lirag ...... y in Type 2 diabetes mellitus.
@ast
Cost-utility analysis of lirag ...... y in Type 2 diabetes mellitus.
@en
P2093
P2860
P1433
P1476
Cost-utility analysis of lirag ...... y in Type 2 diabetes mellitus.
@en
P2093
M J Davies
W J Valentine
P2860
P304
P356
10.1111/J.1464-5491.2011.03429.X
P577
2012-03-01T00:00:00Z